Lilly falls short on Q1 EPS, but diabetes newcomers keep revenue in line

Lilly

Once again, Eli Lilly’s diabetes brands grew for the quarter to help keep its revenues in line with expectations. But the company’s spending grew, too, dragging Q1 EPS below analyst forecasts.

The Indianapolis drugmaker posted non-GAAP EPS of 83 cents, falling just short of the 85 cents Wall Street predicted. It had higher operating expenses to blame--though those were offset by a lower-than-expected tax rate of 17.9%, which kept the shortfall to a minimum.

Revenues, though, hit their spot, checking in at $4.86 billion to surpass the $4.84 billion consensus estimate. That haul represents a 5% increase over last year’s Q1 total, and the company had a crop of new products--which generated $325 million in revenue between them, CFO Derica Rice told shareholders on a conference call--to thank for the increase.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Most of those fell into the diabetes portfolio, with GLP-1 med Trulicity, SGLT2 product Jardiance and long-acting insulin Basaglar all chipping in. Trulicity drummed up $143.6 million in Q1 sales to top expectations of $119 million, while Jardiance--closely watched since it last year became the first diabetes med to lower cardiovascular events in high-risk Type 2 patients--beat on revenue in the U.S., where it posted $29.7 million.

Lilly attributed the Trulicity and Jardiance performances to increased market share for each med--a positive sign considering the hefty competition in both the GLP-1 and the SGLT2 fields. Trulicity’s total share of the GLP-1 field is 17% and growing, and it’s now the second-most-prescribed product in its class, Rice noted. As for Jardiance, its new-to-brand share approached 30% in Q1, nearly doubling what it was last year.

The one diabetes downside for the pharma giant: Humalog, which underperformed forecasts by $100 million to hit $606.3 million for the quarter. That slide measured an 11% decrease over last year’s Q1 total--and a 14% decrease in the U.S.--driven by lower realized prices, Lilly said. But it doesn’t expect that trend to continue all year.

All things considered, Lilly saw it fitting to tweak its guidance slightly. It now think’s it’ll end the year with sales in the $20.6 billion to $21.1 billion range, up from the $20.2 billion to $20.7 billion it earlier predicted.

- read Lilly's release 

Special Report: The top 15 pharma companies by 2014 revenue - Eli Lilly 

Related Articles:
Riding Q4 diabetes growth, Lilly aims for even more with Jardiance
You say you want a revolution? Lilly, BI and Jardiance may trigger one in diabetes​
Lilly, BI's Jardiance posts 'amazing' 14% reduction in major CV events
Cost cuts, diabetes sales help drive Lilly to Q3 beat

Read more on

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.